Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term surviving cancer patients as a source of therapeutic TCR

8 Jan 2020

Abstract excerpt

We have established a platform for the isolation of tumour-specific TCR from T cells of patients who experienced clinical benefit from cancer vaccination. In this review we will present the rationale behind this strategy and discuss the advantages of working with "natural" wild type TCRs. Indeed, the general trend in the field has been to use various modifications to enhance the affinity of such therapeutic TCRs....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31915853
DOI: 10.1007/s00262-019-02468-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term surviving cancer patients as a source of therapeutic TCRPMID 31915853Read ↗

The Anticancer Potential of T Cell Receptor-Engineered T Cells.Semantic proximity Read ↗

Engineering Strategies to Enhance TCR-Based Adoptive T Cell TherapySemantic proximity Read ↗

Emerging Strategies in TCR-Engineered T CellsSemantic proximity Read ↗

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistanceSemantic proximity Read ↗

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.Semantic proximity Read ↗

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cellsSemantic proximity Read ↗

Untouched GMP-Ready Purified Engineered Immune Cells to Treat CancerSemantic proximity Read ↗

Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy.Semantic proximity Read ↗

Engineered T cells for anti-cancer therapySemantic proximity Read ↗

Re‐adapting T cells for cancer therapy: from mouse models to clinical trialsSemantic proximity Read ↗

A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 daysSemantic proximity Read ↗

Identification of T-cell epitopes for cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.